Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — ...
In this randomized controlled trial, biweekly injections of the novel glucagon-like peptide-1 receptor agonist (GLP-1RA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results